ClinicalTrials.gg
CompletedNCT02573259Updated Dec 13, 2021Results posted

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

A Phase 1 interventional study of PF-06801591 and PF-06801591 in Part 1, MELANOMA and SCCHN, sponsored by Pfizer. Completed at 67 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-13.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.

Enrollment
15th of 48
147 · median 77
Started
2016
with 1 other
Phase 1
27 of 52
1 open now
Registered
23rd of 52
by date

Among the 52 studies in Melanoma by Pfizer, this one is the 15th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2016, is one of 27 in phase 1, and was the 23rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Melanoma by Pfizer, or all of them as a file.
02

Study summary

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.

Read the detailed description

Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety, efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous (SC) in previously treated adult patients with locally advanced or metastatic melanoma, squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell lung carcinoma (NSCLC), urothelial carcinoma or other solid tumors.

The first part of the study, Part 1 dose escalation, was designed to assess the safety and tolerability of increasing dose levels of IV or SC administered PF-06801591 to establish the maximum tolerated dose (MTD) using a modified Toxicity Probability Interval (mTPI) design. Part 2 expansion is designed to further evaluate the safety and efficacy of 300 mg of PF-06801591 administered SC once every 4 weeks in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose (RP2D). Part 1 enrollment has completed, enrollment will only be allowed for Part 2.

03

Conditions studied

  • Part 1
  • MELANOMA
  • SCCHN
  • OVCA
  • SARCOMA
  • OTHER SOLID TUMORS
  • Part 1 and 2
  • NSCLC
  • UROTHELIAL CARCINOMA

Keywords

  • efficacy
  • safety
  • pharmacokinetics
  • pharmacodynamics
  • open label
  • dose response
  • multiple ascending dose
  • immunogenicity
  • recommended phase 2 dose
  • subcutaneous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of locally advanced or NSCLC or urothelial carcinoma who have progressed on or were intolerant to standard of care systemic therapy, or for whom standard of care systemic therapy was refused (refusal must be documented) or unavailable.
  • No prior treatment with or anti-PD-L1 therapy.
  • NSCLC patients whose tumor is not known to have ALK or EGFR mutations must have progressed on or after no more than 1 prior line of platinum-containing systemic therapy or were intolerant or refused standard of care systemic therapy.
  • NSCLC patients whose tumor is known to have ALK or EGFR mutation must have received prior systemic therapies that only include 1 or more lines of ALK or EGFR targeting drugs and chemotherapy limited to 1 line of a platinum-based regimen and they must have progressed on or after both types of therapies.
  • Urothelial carcinoma patients must have received up to 2 lines of prior systemic therapy and progressed on or after, experienced disease recurrence within 12 months of or adjuvant treatment, were intolerant to, ineligible or refused platinum-containing systemic therapy. If urothelial cancer patients are treatment naïve and eligible for platinum-containing systemic therapy but are refusing platinum chemotherapy, they must also be documented to have previous PD-L1 high status.
  • Provide archived tumor tissue sample taken within the past 2 years or provide a fresh tumor sample.
  • At least one as defined by version 1.1.
  • Adequate renal, liver, thyroid and bone marrow function.
  • Performance status 0 or 1.
  • Patient is capable of receiving study treatment for at least 8 weeks.

Exclusion criteria

Exclusion Criteria (Part 2 Only)

  • Active brain or .
  • Active, known or suspected disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Diagnosis of prior immunodeficiency or organ transplant requiring therapy or prior allogeneic bone marrow or hematopoietic stem cell transplant.
  • Patients with a condition requiring systemic treatment with either (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Patients with a history of interstitial lung disease, non-infectious pneumonitis, or active pulmonary tuberculosis. Those with active lung infections requiring treatment are also excluded.
  • History of Grade ≥3 immune mediated AE (including /ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune modulatory therapy (eg, , co-stimulatory agents, etc.) and required immunosuppressive therapy.
  • Active or C, /AIDS.
  • Other potentially within past 5 years.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Arm 1 PF-06801591

    0.5 mg/kg IV every 21 days (Part 1)

    Drug: PF-06801591

  • Experimental
    Arm 2 PF-06801591

    1.0 mg/kg IV every 21 days (Part 1)

    Drug: PF-06801591

  • Experimental
    Arm 3 PF-06801591

    3.0 mg/kg IV every 21 days (Part 1)

    Drug: PF-06801591

  • Experimental
    Arm 4 PF-06801591

    10 mg/kg IV every 21 days (Part 1)

    Drug: PF-06801591

  • Experimental
    Arm 5 PF-06801591

    300 mg SC every 28 days (Part 1 and 2)

    Drug: PF-06801591

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1

    DLT was defined as any of the following drug-related adverse events (AEs) occurring during the first cycle (21 days for IV dosing, 28 days for SC dosing) in Part 1: Grade 5 AE; Grade 4 neutropenia lasting \>5 days from initiation of granulocyte colony stimulating factor; Grade 4 thrombocytopenia with bleeding; Platelet transfusion requirement or a platelet count \<10,000/uL; Grade 4 non-hematologic AE; Grade 3 AE lasting \>7 days despite optimal supportive care; Grade 3 central nervous system AE regardless of duration; met criteria for drug induced liver injury. Severity of AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Time frame: Cycle 1 in Part 1 (21 days for IV administration of PF-06801591; 28 days for SC administration of PF-06801591)

  2. Number of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

    AE = any untoward medical occurrence in participant who received study treatment without regard to possibility of causal relationship. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  3. Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

    Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  4. Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2

    Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Time frame: Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  5. Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2

    ORR was defined as percentage of participants with confirmed objective response (OR) of complete response (CR) and partial response (PR) based on RECIST version 1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

  6. Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2

    ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of PF-06801591 - Part 1

    Cmax was the maximum concentration after dose administration observed directly from the data.

    Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  2. AUClast of PF-06801591 in Part 1.

    Area Under the Concentration Versus Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Prior to the Next Dose (AUClast) of PF-06801591 - Part 1

    Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1 in Part 1

  3. Clearance (CL) of PF-06801591 - Part 1

    CL for IV dosing. CL was calculated by dose / AUCtau for Cycles 1 and 4 IV dosing. AUCtau was defined as area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for every 3 weeks (Q3W) IV dosing reporting arm.

    Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  4. Volume of Distribution at Steady State (Vss) of PF-06801591 - Part 1

    Steady state volume of distribution of PF-0680159 for IV dosing. Vss was calculated by CL\*MRT. CL was the clearance for IV dosing. MRT was the mean residence time calculated for a single IV dose as AUMCinf/AUCinf - (DOF/2). AUMCinf was the area under the moment curve from time 0 extrapolated to infinity. DOF was the duration of infusion. AUCinf was the area under the serum concentration time profile from time 0 extrapolated to infinity.

    Time frame: Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  5. Accumulation Ratio (Rac) of PF-06801591 - Part 1

    Rac was calculated by (Cycle 4 AUCtau) / (Cycle 1 AUCtau). AUCtau was Area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for Q3W IV dosing and tau = 672 hours for every 4 weeks (Q4W) SC dosing.

    Time frame: Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1

  6. Terminal Elimination Half-Life (t1/2) of PF-06801591 - Part 1

    t1/2 was calculated by Loge(2)/kel. kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.

    Time frame: Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1

  7. Number of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 2

    Number of participants with ADA positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was ADA positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were ADA positive at baseline but did not become boosted post-treatment were considered as ADA negative.

    Time frame: Baseline up to end of treatment (maximum of 851 days)

  8. Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2

    Number of participants with NAb positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was NAb positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were NAb positive at baseline but did not become boosted post-treatment were considered as NAb negative.

    Time frame: Baseline up to end of treatment (maximum of 851 days)

  9. Percentage of Baseline PD-1 Receptor Occupancy (RO) by PF-06801591 - Part 1

    PD-1 RO by sasanlimab was measured by the reduction of free receptor on the surface of CD8+ effector cells (CD3+, CD4-, CD8+, CD45RA+, CCR7-, CD279+) and CD8+ effector memory cells (CD3+, CD4-, CD8+, CD45RA-, CCR7-, CD279+) presented in pre- and postdose whole blood samples by flow cytometry. Percentage of baseline (ie, normalized change from baseline) PD-1 RO were calculated as \[(percentage of cells at Cycle X Day X)/(percentage of cells at baseline)\]\*100, and are reported for this outcome measure. Baseline was defined as the most recent non-missing value prior to dosing.

    Time frame: Baseline, Days 1, 8, 15, 21 of Cycle 1, Day 1 of Cycles 2, 3, 5, Days 1, 15, 21 of Cycle 4, and end of treatment (EOT) in Part 1 (cycle = 21 days for IV dosing; cycle = 28 days for SC dosing)

  10. Number of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 1

    Number of participants achieving confirmed OR based on RECIST version 1.1 in Part 1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

    Time frame: Baseline up to end of treatment in Part 1 (maximum of 1606 days)

  11. Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1

    Number of participants achieving confirmed OR based on irRECIST in Part 1. OR = irCR + irPR. Overall immune related complete response (irCR) was defined as complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \<10 mm. Overall immune related partial response (irPR) was defined as sum of the diameters (longest for non nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases \>=30%.

    Time frame: Baseline up to end of treatment in Part 1 (maximum of 1606 days)

  12. Progression-Free Survival (PFS) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

    PFS was defined as the time from initiation of study intervention to first documentation of tumor progression or to death due to any cause, whichever occurred first. PFS was analyzed by the Kaplan-Meier approach for each tumor type. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.

    Time frame: Baseline up to end of treatment (maximum of 1606 days)

  13. Duration of Stable Disease (DOSD) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

    DOSD was analyzed by the Kaplan-Meier approach for each tumor type. Stable disease (SD) was defined as not qualifying for complete response (CR), partial response (PR), or progression. All target lesions must have been assessed. Stable could follow PR only in the rare case that the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.

    Time frame: Baseline up to end of treatment (maximum of 1606 days)

  14. Duration of Response (DOR) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

    DOR was defined as the time from start date (which was the date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.

    Time frame: Baseline up to end of treatment (maximum of 1606 days)

  15. Time to Response (TTR) Based on RECIST Version 1.1 - Part 2

    TTR was the time to confirmed or unconfirmed complete response (CR) or partial response (PR) based on investigator assessment per RECIST v1.1 by tumor type. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

  16. Time to Progression (TTP) Based on RECIST Version 1.1 and irRECIST - Part 2

    TTP was the time to objective progression. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. TTP was analyzed by the Kaplan-Meier approach for each tumor type.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

  17. Median Time to Death - Part 2

    Median time to death was analyzed by the Kaplan-Meier approach for each tumor type.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

  18. Probability of Survival at 6 Months, 1 Year, and 2 Years - Part 2

    Probability of survival was calculated from the product-limit method.

    Time frame: Baseline up to end of treatment in Part 2 (maximum of 851 days)

  19. Trough PF-06801591 Concentrations (Ctrough) - Part 2

    Trough PF-06801591 Concentrations (Ctrough) - Part 2. Ctrough was directly observed from data.

    Time frame: Pre-dose on Day 1 of Cycles 2-6, 9, 12, 15, 18, 21, 24, and Follow-up Day 28 in Part 2

07

Results

Posted Dec 13, 2021

Participant flow

Participant flow — Overall Study
MilestonePart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Started2887156839
Treated2887156838
Completed10212105
Not completed1866135834
Withdrew: Death165693221
Withdrew: Lost to follow-up0000021
Withdrew: Participant refused further follow-up02103207
Withdrew: Other0000145

Outcome measures

PrimaryPercentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1

DLT was defined as any of the following drug-related adverse events (AEs) occurring during the first cycle (21 days for IV dosing, 28 days for SC dosing) in Part 1: Grade 5 AE; Grade 4 neutropenia lasting \>5 days from initiation of granulocyte colony stimulating factor; Grade 4 thrombocytopenia with bleeding; Platelet transfusion requirement or a platelet count \<10,000/uL; Grade 4 non-hematologic AE; Grade 3 AE lasting \>7 days despite optimal supportive care; Grade 3 central nervous system AE regardless of duration; met criteria for drug induced liver injury. Severity of AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

Time frame:
Cycle 1 in Part 1 (21 days for IV administration of PF-06801591; 28 days for SC administration of PF-06801591)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1
Percentage of ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 100000
PrimaryNumber of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

AE = any untoward medical occurrence in participant who received study treatment without regard to possibility of causal relationship. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

Time frame:
Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2
ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Participants with AEs2787156236
Participants with SAEs133331813
Participants with maximum Grade 3 or 4 AEs223241813
Participants with maximum Grade 5 AEs0112085
PrimaryNumber of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

Time frame:
Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2
ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Participants with AEs2676134217
Participants with SAEs0000013
Participants with maximum of Grade 3 or 4 AEs1111195
Participants with maximum of Grade 5 AEs0000000
PrimaryNumber of Participants With Laboratory Test Abnormalities - Part 1 and Part 2

Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

Time frame:
Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2
ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
ANEMIA — Grade 002111166
ANEMIA — Grade 1114553816
ANEMIA — Grade 214318139
ANEMIA — Grade 30000117
ANEMIA — Grade 4NANANANANANANA
HEMOGLOBIN INCREASED — Grade 02787156035
HEMOGLOBIN INCREASED — Grade 10000073
HEMOGLOBIN INCREASED — Grade 20000010
HEMOGLOBIN INCREASED — Grade 30000000
HEMOGLOBIN INCREASED — Grade 4NANANANANANANA
LYMPHOCYTE COUNT DECREASED — Grade 0030192720
LYMPHOCYTE COUNT DECREASED — Grade 1002122111
LYMPHOCYTE COUNT DECREASED — Grade 222641155
LYMPHOCYTE COUNT DECREASED — Grade 30101352
LYMPHOCYTE COUNT DECREASED — Grade 40100000
LYMPHOCYTE COUNT INCREASED — Grade 02787146337
LYMPHOCYTE COUNT INCREASED — Grade 1NANANANANANANA
LYMPHOCYTE COUNT INCREASED — Grade 20000151
LYMPHOCYTE COUNT INCREASED — Grade 30000000
LYMPHOCYTE COUNT INCREASED — Grade 4NANANANANANANA
NEUTROPHIL COUNT DECREASED — Grade 02675136135
NEUTROPHIL COUNT DECREASED — Grade 10112140
NEUTROPHIL COUNT DECREASED — Grade 20000023
NEUTROPHIL COUNT DECREASED — Grade 30000100
NEUTROPHIL COUNT DECREASED — Grade 40000010
PLATELET COUNT DECREASED — Grade 01776125633
PLATELET COUNT DECREASED — Grade 110113125
PLATELET COUNT DECREASED — Grade 20000000
PLATELET COUNT DECREASED — Grade 30000000
PLATELET COUNT DECREASED — Grade 40000000
WHITE BLOOD CELL DECREASED — Grade 01553106234
WHITE BLOOD CELL DECREASED — Grade 11134453
WHITE BLOOD CELL DECREASED — Grade 20100101
WHITE BLOOD CELL DECREASED — Grade 30000010
WHITE BLOOD CELL DECREASED — Grade 40000000
ALANINE AMINOTRANSFERASE INCREASED — Grade 02784144531
ALANINE AMINOTRANSFERASE INCREASED — Grade 100031193
ALANINE AMINOTRANSFERASE INCREASED — Grade 20000013
ALANINE AMINOTRANSFERASE INCREASED — Grade 30000031
ALANINE AMINOTRANSFERASE INCREASED — Grade 40000000
ALKALINE PHOSPHATASE INCREASED — Grade 0145463621
ALKALINE PHOSPHATASE INCREASED — Grade 1023272211
ALKALINE PHOSPHATASE INCREASED — Grade 21100274
ALKALINE PHOSPHATASE INCREASED — Grade 30001032
ALKALINE PHOSPHATASE INCREASED — Grade 40000000
ASPARTATE AMINOTRANSFERASE INCREASED — Grade 00575114423
ASPARTATE AMINOTRANSFERASE INCREASED — Grade 1221141713
ASPARTATE AMINOTRANSFERASE INCREASED — Grade 20000051
ASPARTATE AMINOTRANSFERASE INCREASED — Grade 30001010
ASPARTATE AMINOTRANSFERASE INCREASED — Grade 40000001
BLOOD BILIRUBIN INCREASED — Grade 01776135834
BLOOD BILIRUBIN INCREASED — Grade 10010163
BLOOD BILIRUBIN INCREASED — Grade 21000131
BLOOD BILIRUBIN INCREASED — Grade 30001010
BLOOD BILIRUBIN INCREASED — Grade 40000000
CPK INCREASED — Grade 0—————3—
CPK INCREASED — Grade 1—————0—
CPK INCREASED — Grade 2—————0—
CPK INCREASED — Grade 3—————0—
CPK INCREASED — Grade 4—————0—
CREATININE INCREASED — Grade 0003013582
CREATININE INCREASED — Grade 116471630
CREATININE INCREASED — Grade 21110135
CREATININE INCREASED — Grade 30000011
CREATININE INCREASED — Grade 40000000
GGT INCREASED — Grade 00————00
GGT INCREASED — Grade 11————21
GGT INCREASED — Grade 20————10
GGT INCREASED — Grade 30————11
GGT INCREASED — Grade 40————00
HYPERCALCEMIA — Grade 02787135131
HYPERCALCEMIA — Grade 100001155
HYPERCALCEMIA — Grade 20000010
HYPERCALCEMIA — Grade 30000100
HYPERCALCEMIA — Grade 40000012
HYPERGLYCEMIA — Grade 02586142412
HYPERGLYCEMIA — Grade 1000003121
HYPERGLYCEMIA — Grade 200000104
HYPERGLYCEMIA — Grade 30200131
HYPERGLYCEMIA — Grade 40001000
HYPERKALEMIA — Grade 02677154827
HYPERKALEMIA — Grade 10010086
HYPERKALEMIA — Grade 200000113
HYPERKALEMIA — Grade 30100012
HYPERKALEMIA — Grade 40000000
HYPERMAGNESEMIA — Grade 01775155535
HYPERMAGNESEMIA — Grade 11012063
HYPERMAGNESEMIA — Grade 2NANANANANANANA
HYPERMAGNESEMIA — Grade 30000070
HYPERMAGNESEMIA — Grade 40000000
HYPERNATREMIA — Grade 02586135135
HYPERNATREMIA — Grade 10201282
HYPERNATREMIA — Grade 20000070
HYPERNATREMIA — Grade 30000020
HYPERNATREMIA — Grade 40000001
HYPOALBUMINEMIA — Grade 01553104023
HYPOALBUMINEMIA — Grade 1022421811
HYPOALBUMINEMIA — Grade 210102104
HYPOALBUMINEMIA — Grade 30000100
HYPOALBUMINEMIA — Grade 4NANANANANANANA
HYPOCALCEMIA — Grade 01655134930
HYPOCALCEMIA — Grade 111321127
HYPOCALCEMIA — Grade 20000170
HYPOCALCEMIA — Grade 30000000
HYPOCALCEMIA — Grade 40000001
HYPOGLYCEMIA — Grade 02787156032
HYPOGLYCEMIA — Grade 10000086
HYPOGLYCEMIA — Grade 20000000
HYPOGLYCEMIA — Grade 30000000
HYPOGLYCEMIA — Grade 40000000
HYPOKALEMIA — Grade 01756106133
HYPOKALEMIA — Grade 1NANANANANANANA
HYPOKALEMIA — Grade 21031473
HYPOKALEMIA — Grade 30000102
HYPOKALEMIA — Grade 40000000
HYPOMAGNESEMIA — Grade 0267784229
HYPOMAGNESEMIA — Grade 101105148
HYPOMAGNESEMIA — Grade 20000281
HYPOMAGNESEMIA — Grade 30000040
HYPOMAGNESEMIA — Grade 40000000
HYPONATREMIA — Grade 0047584525
HYPONATREMIA — Grade 1021151910
HYPONATREMIA — Grade 2NANANANANANANA
HYPONATREMIA — Grade 32001232
HYPONATREMIA — Grade 40100011
HYPOPHOSPHATEMIA — Grade 01567155627
HYPOPHOSPHATEMIA — Grade 10000037
HYPOPHOSPHATEMIA — Grade 21220074
HYPOPHOSPHATEMIA — Grade 30000010
HYPOPHOSPHATEMIA — Grade 40000000
LIPASE INCREASED — Grade 02457135023
LIPASE INCREASED — Grade 103100117
LIPASE INCREASED — Grade 20010043
LIPASE INCREASED — Grade 30010113
LIPASE INCREASED — Grade 40000121
SERUM AMYLASE INCREASED — Grade 01676134523
SERUM AMYLASE INCREASED — Grade 1111011610
SERUM AMYLASE INCREASED — Grade 20001042
SERUM AMYLASE INCREASED — Grade 30000133
SERUM AMYLASE INCREASED — Grade 40000000
PROTEINURIA — Grade 0054194615
PROTEINURIA — Grade 1123361517
PROTEINURIA — Grade 21012055
PROTEINURIA — Grade 30000001
PROTEINURIA — Grade 40000000
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 01654114419
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 1113341915
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 20000043
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 30000011
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED — Grade 4NANANANANANANA
INR INCREASED — Grade 02564123931
INR INCREASED — Grade 102133254
INR INCREASED — Grade 20010011
INR INCREASED — Grade 30000030
INR INCREASED — Grade 4NANANANANANANA
PrimaryObjective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2

ORR was defined as percentage of participants with confirmed objective response (OR) of complete response (CR) and partial response (PR) based on RECIST version 1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Number · Percentage
Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2
PercentagePart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 216.4 (8.5 to 27.5)18.4 (7.7 to 34.3)
PrimaryObjective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2

ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2
Percentage of ParticipantsPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 219.4 (10.8 to 30.9)21.1 (9.6 to 37.3)
SecondaryMaximum Plasma Concentration (Cmax) of PF-06801591 - Part 1

Cmax was the maximum concentration after dose administration observed directly from the data.

Time frame:
Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
Reported as:
Geometric mean · ug/mL
Maximum Plasma Concentration (Cmax) of PF-06801591 - Part 1
ug/mLPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Cycle 1 Day 1NA ± NA21.52 ± 2369.63 ± 28217.2 ± 3621.24 ± 50
Cycle 4 Day 1NA ± NA30.10 ± 1686.34 ± 52402.6 ± 4256.48 ± 29
SecondaryAUClast of PF-06801591 in Part 1.

Area Under the Concentration Versus Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Prior to the Next Dose (AUClast) of PF-06801591 - Part 1

Time frame:
Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1 in Part 1
Reported as:
Geometric mean · ug*hr/mL
AUClast of PF-06801591 in Part 1.
ug*hr/mLPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
AUClast of PF-06801591 in Part 1.NA ± NA4700 ± 4114770 ± 2746780 ± 499923 ± 65
SecondaryClearance (CL) of PF-06801591 - Part 1

CL for IV dosing. CL was calculated by dose / AUCtau for Cycles 1 and 4 IV dosing. AUCtau was defined as area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for every 3 weeks (Q3W) IV dosing reporting arm.

Time frame:
Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
Reported as:
Geometric mean · L/hr
Clearance (CL) of PF-06801591 - Part 1
L/hrPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)
Cycle 1 Day 1—NA ± NA——
Cycle 4 Day 1NA ± NANA ± NA0.006045 ± 570.004984 ± 14
SecondaryVolume of Distribution at Steady State (Vss) of PF-06801591 - Part 1

Steady state volume of distribution of PF-0680159 for IV dosing. Vss was calculated by CL\*MRT. CL was the clearance for IV dosing. MRT was the mean residence time calculated for a single IV dose as AUMCinf/AUCinf - (DOF/2). AUMCinf was the area under the moment curve from time 0 extrapolated to infinity. DOF was the duration of infusion. AUCinf was the area under the serum concentration time profile from time 0 extrapolated to infinity.

Time frame:
Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1
Reported as:
Geometric mean · L
Volume of Distribution at Steady State (Vss) of PF-06801591 - Part 1
LPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)
Cycle 1 Day 1—NA ± NA——
SecondaryAccumulation Ratio (Rac) of PF-06801591 - Part 1

Rac was calculated by (Cycle 4 AUCtau) / (Cycle 1 AUCtau). AUCtau was Area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for Q3W IV dosing and tau = 672 hours for every 4 weeks (Q4W) SC dosing.

Time frame:
Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1
Reported as:
Geometric mean · Ratio
Accumulation Ratio (Rac) of PF-06801591 - Part 1
RatioPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Accumulation Ratio (Rac) of PF-06801591 - Part 1NA ± NANA ± NANA ± NA2.360 ± 122.073 ± 31
SecondaryTerminal Elimination Half-Life (t1/2) of PF-06801591 - Part 1

t1/2 was calculated by Loge(2)/kel. kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.

Time frame:
Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1
Reported as:
Mean · Days
Terminal Elimination Half-Life (t1/2) of PF-06801591 - Part 1
DaysPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Cycle 1 Day 1—NA ± NA———
Cycle 4 Day 1————NA ± NA
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 2

Number of participants with ADA positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was ADA positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were ADA positive at baseline but did not become boosted post-treatment were considered as ADA negative.

Time frame:
Baseline up to end of treatment (maximum of 851 days)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 2
ParticipantsPart 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)
Number of Participants With Anti-Drug Antibody (ADA) Against PF-06801591 - Part 1 and Part 21531100
SecondaryNumber of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2

Number of participants with NAb positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was NAb positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were NAb positive at baseline but did not become boosted post-treatment were considered as NAb negative.

Time frame:
Baseline up to end of treatment (maximum of 851 days)
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2
ParticipantsPart 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)
Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 20310000
SecondaryPercentage of Baseline PD-1 Receptor Occupancy (RO) by PF-06801591 - Part 1

PD-1 RO by sasanlimab was measured by the reduction of free receptor on the surface of CD8+ effector cells (CD3+, CD4-, CD8+, CD45RA+, CCR7-, CD279+) and CD8+ effector memory cells (CD3+, CD4-, CD8+, CD45RA-, CCR7-, CD279+) presented in pre- and postdose whole blood samples by flow cytometry. Percentage of baseline (ie, normalized change from baseline) PD-1 RO were calculated as \[(percentage of cells at Cycle X Day X)/(percentage of cells at baseline)\]\*100, and are reported for this outcome measure. Baseline was defined as the most recent non-missing value prior to dosing.

Time frame:
Baseline, Days 1, 8, 15, 21 of Cycle 1, Day 1 of Cycles 2, 3, 5, Days 1, 15, 21 of Cycle 4, and end of treatment (EOT) in Part 1 (cycle = 21 days for IV dosing; cycle = 28 days for SC dosing)
Reported as:
Median · Percentage of Baseline
Percentage of Baseline PD-1 Receptor Occupancy (RO) by PF-06801591 - Part 1
Percentage of BaselinePart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Cycle 1 Day 10.00 (0.0 to 0.0)0.00 (0.0 to 0.1)0.56 (0.0 to 4.0)0.02 (0.0 to 0.6)0.32 (0.0 to 3.0)
Cycle 1 Day 80.00 (0.0 to 0.0)0.00 (0.0 to 0.0)0.00 (0.0 to 0.2)0.00 (0.0 to 1.4)0.00 (0.0 to 3.1)
Cycle 1 Day 150.00 (0.0 to 0.0)0.00 (0.0 to 1.3)0.00 (0.0 to 0.6)0.00 (0.0 to 7.7)0.57 (0.0 to 4.5)
Cycle 1 Day 21————0.00 (0.0 to 1.0)
Cycle 2 Day 11.48 (0.0 to 3.0)0.04 (0.0 to 1.7)0.82 (0.0 to 3.0)0.00 (0.0 to 1.0)0.00 (0.0 to 4.7)
Cycle 3 Day 10.00 (0.0 to 0.0)0.00 (0.0 to 0.2)0.47 (0.0 to 3.1)0.00 (0.0 to 2.3)0.00 (0.0 to 4.7)
Cycle 4 Day 10.80 (0.5 to 1.1)0.00 (0.0 to 0.0)0.05 (0.0 to 23.2)0.00 (0.0 to 2.1)0.00 (0.0 to 2.1)
Cycle 4 Day 150.00 (0.0 to 0.0)0.00 (0.0 to 2.6)0.00 (0.0 to 0.0)0.00 (0.0 to 0.7)0.00 (0.0 to 1.4)
Cycle 4 Day 21————1.31 (0.0 to 1.4)
Cycle 5 Day 10.00 (0.0 to 0.0)0.00 (0.0 to 0.0)0.00 (0.0 to 3.2)0.00 (0.0 to 1.2)0.00 (0.0 to 1.5)
EOT—0.00 (0.0 to 0.5)0.00 (0.0 to 0.7)0.00 (0.0 to 0.5)0.17 (0.0 to 2.7)
SecondaryNumber of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 1

Number of participants achieving confirmed OR based on RECIST version 1.1 in Part 1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

Time frame:
Baseline up to end of treatment in Part 1 (maximum of 1606 days)
Reported as:
Count of participants · Participants
Number of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 1
ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Number of Participants Achieving Objective Response (OR) Based on RECIST Version 1.1 - Part 112121
SecondaryNumber of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1

Number of participants achieving confirmed OR based on irRECIST in Part 1. OR = irCR + irPR. Overall immune related complete response (irCR) was defined as complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \<10 mm. Overall immune related partial response (irPR) was defined as sum of the diameters (longest for non nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases \>=30%.

Time frame:
Baseline up to end of treatment in Part 1 (maximum of 1606 days)
Reported as:
Count of participants · Participants
Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1
ParticipantsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])
Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 112121
SecondaryProgression-Free Survival (PFS) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

PFS was defined as the time from initiation of study intervention to first documentation of tumor progression or to death due to any cause, whichever occurred first. PFS was analyzed by the Kaplan-Meier approach for each tumor type. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.

Time frame:
Baseline up to end of treatment (maximum of 1606 days)
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
MonthsPart 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV])Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
RECIST v1.14.7 (1.4 to 8.3)3.0 (1.6 to 6.0)3.7 (1.9 to 5.5)2.9 (1.9 to 3.8)
irRECIST4.9 (1.4 to 13.8)4.5 (1.9 to 13.7)5.5 (2.8 to 8.2)3.8 (2.0 to 14.5)
SecondaryDuration of Stable Disease (DOSD) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

DOSD was analyzed by the Kaplan-Meier approach for each tumor type. Stable disease (SD) was defined as not qualifying for complete response (CR), partial response (PR), or progression. All target lesions must have been assessed. Stable could follow PR only in the rare case that the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.

Time frame:
Baseline up to end of treatment (maximum of 1606 days)
Reported as:
Median · Months
Duration of Stable Disease (DOSD) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
MonthsPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
RECIST v1.1NANA (4.6 to NA)24.3 (13.8 to 34.9)5.7 (2.5 to 8.8)6.0 (3.8 to 7.3)6.5 (3.7 to 10.1)8.5 (3.7 to NA)
irRECISTNANA (4.6 to NA)29.0 (20.0 to 37.9)5.7 (2.5 to 8.8)13.7 (3.3 to 13.7)7.5 (5.4 to 18.4)14.5 (3.7 to NA)
SecondaryDuration of Response (DOR) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2

DOR was defined as the time from start date (which was the date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.

Time frame:
Baseline up to end of treatment (maximum of 1606 days)
Reported as:
Median · Months
Duration of Response (DOR) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2
MonthsPart 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV])Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
RECIST v1.19.7 (3.7 to NA)NA21.8 (5.8 to NA)13.9 (3.8 to NA)
irRECIST13.0 (4.1 to NA)NA22.1 (6.8 to NA)NA (4.6 to NA)
SecondaryTime to Response (TTR) Based on RECIST Version 1.1 - Part 2

TTR was the time to confirmed or unconfirmed complete response (CR) or partial response (PR) based on investigator assessment per RECIST v1.1 by tumor type. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). All target lesions must have been assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must have been assessed.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Median · Months
Time to Response (TTR) Based on RECIST Version 1.1 - Part 2
MonthsPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Time to Response (TTR) Based on RECIST Version 1.1 - Part 22.71 (1.4 to 12.0)2.33 (1.4 to 5.5)
SecondaryTime to Progression (TTP) Based on RECIST Version 1.1 and irRECIST - Part 2

TTP was the time to objective progression. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. TTP was analyzed by the Kaplan-Meier approach for each tumor type.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Median · Months
Time to Progression (TTP) Based on RECIST Version 1.1 and irRECIST - Part 2
MonthsPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
RECIST v1.13.7 (1.9 to 5.7)3.7 (1.9 to 8.5)
irRECIST6.5 (3.7 to 10.3)8.5 (2.5 to 19.4)
SecondaryMedian Time to Death - Part 2

Median time to death was analyzed by the Kaplan-Meier approach for each tumor type.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Median · Months
Median Time to Death - Part 2
MonthsPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Median Time to Death - Part 214.7 (7.1 to NA)10.9 (7.2 to 19.9)
SecondaryProbability of Survival at 6 Months, 1 Year, and 2 Years - Part 2

Probability of survival was calculated from the product-limit method.

Time frame:
Baseline up to end of treatment in Part 2 (maximum of 851 days)
Reported as:
Number · Probability
Probability of Survival at 6 Months, 1 Year, and 2 Years - Part 2
ProbabilityPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
6 Months0.773 (0.647 to 0.859)0.711 (0.527 to 0.833)
1 Year0.547 (0.407 to 0.667)0.471 (0.290 to 0.633)
2 Years0.403 (0.265 to 0.537)0.286 (0.127 to 0.467)
SecondaryTrough PF-06801591 Concentrations (Ctrough) - Part 2

Trough PF-06801591 Concentrations (Ctrough) - Part 2. Ctrough was directly observed from data.

Time frame:
Pre-dose on Day 1 of Cycles 2-6, 9, 12, 15, 18, 21, 24, and Follow-up Day 28 in Part 2
Reported as:
Geometric mean · ug/mL
Trough PF-06801591 Concentrations (Ctrough) - Part 2
ug/mLPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UC
Cycle 2 Day 114.97 ± 4814.34 ± 73
Cycle 3 Day 122.54 ± 3720.15 ± 84
Cycle 4 Day 123.55 ± 5323.77 ± 60
Cycle 5 Day 123.58 ± 4119.32 ± 186
Cycle 6 Day 129.67 ± 3617.13 ± 249
Cycle 9 Day 129.01 ± 3629.88 ± 30
Cycle 12 Day 134.29 ± 1612.74 ± 770
Cycle 15 Day 140.90 ± 2222.10 ± 56
Cycle 18 Day 135.09 ± 2520.17 ± 75
Cycle 21 Day 127.16 ± 2522.11 ± 55
Cycle 24 Day 130.81 ± 1638.02 ± 38
Follow-up Day 2843.62 ± 3335.17 ± 32

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (up to a maximum of 237 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])1/2 (50%)1/2 (50%)2/2 (100%)
Part 1: PF-06801591 1 mg/kg (IV)6/8 (75%)3/8 (37.5%)7/8 (87.5%)
Part 1: PF-06801591 3 mg/kg (IV)5/8 (62.5%)3/8 (37.5%)8/8 (100%)
Part 1: PF-06801591 10 mg/kg (IV)6/7 (85.7%)3/7 (42.9%)7/7 (100%)
Part 1: PF-06801591 300 mg (Subcutaneously [SC])10/15 (66.7%)3/15 (20%)15/15 (100%)
Part 1: PF-06801591 IV Total18/25 (72%)10/25 (40%)24/25 (96%)
Part 1: PF-06801591 IV and SC Total28/40 (70%)13/40 (32.5%)39/40 (97.5%)
Part 2: PF-06801591 300 mg (SC) for NSCLC33/68 (48.5%)18/68 (26.5%)59/68 (86.8%)
Part 2: PF-06801591 300 mg (SC) for UC21/38 (55.3%)13/38 (34.2%)33/38 (86.8%)
Part 2: PF-06801591 NSCLC and UC Total54/106 (50.9%)31/106 (29.2%)92/106 (86.8%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 1: PF-06801591 IV TotalPart 1: PF-06801591 IV and SC TotalPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCPart 2: PF-06801591 NSCLC and UC Total
Upper gastrointestinal haemorrhageGastrointestinal disorders1/21/80/80/70/152/252/400/680/380/106
Disease progressionGeneral disorders0/21/81/82/70/154/254/403/682/385/106
Atrial fibrillationCardiac disorders0/20/80/81/70/151/251/400/680/380/106
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/20/80/81/70/151/251/400/680/380/106
Intestinal obstructionGastrointestinal disorders0/21/80/80/70/151/251/400/680/380/106
Small intestinal obstructionGastrointestinal disorders0/20/81/80/71/151/252/400/680/380/106
Postoperative wound infectionInfections and infestations0/20/81/80/70/151/251/400/680/380/106
DysphagiaGastrointestinal disorders0/20/80/80/71/150/251/401/680/381/106
PneumoniaInfections and infestations0/20/80/80/71/150/251/401/680/381/106
SepsisInfections and infestations0/20/80/80/71/150/251/400/681/381/106
Most frequent other events
Showing 10 of 210
Most frequent other events
EventPart 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 1: PF-06801591 IV TotalPart 1: PF-06801591 IV and SC TotalPart 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCPart 2: PF-06801591 NSCLC and UC Total
ConstipationGastrointestinal disorders2/24/82/83/72/1511/2513/402/684/386/106
NauseaGastrointestinal disorders2/21/83/80/76/156/2512/405/683/388/106
VomitingGastrointestinal disorders2/22/82/81/75/157/2512/401/680/381/106
Generalised oedemaGeneral disorders2/23/84/84/75/1513/2518/400/680/380/106
Mucosal inflammationGeneral disorders2/21/80/81/71/154/255/400/680/380/106
Urinary tract infectionInfections and infestations2/20/81/81/72/154/256/402/685/387/106
Blood creatinine increasedInvestigations2/21/81/80/72/154/256/403/683/386/106
Decreased appetiteMetabolism and nutrition disorders2/23/81/80/77/156/2513/409/683/3812/106
Back painMusculoskeletal and connective tissue disorders2/21/81/80/74/154/258/403/686/389/106
HypothyroidismEndocrine disorders1/21/80/81/71/153/254/405/684/389/106

Baseline characteristics

Baseline population included all enrolled participants who received at least 1 dose of study treatment. One participant who enrolled in Part 2: PF-06801591 300 mg (SC) for UC arm was not treated.

Age, Customized
Age, Customized(Participants)Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCTotal
18-44 Years00110114
45-64 Years135310281666
>=65 Years15235392176
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCTotal
Female265411151356
Male02334532590
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])Part 1: PF-06801591 1 mg/kg (IV)Part 1: PF-06801591 3 mg/kg (IV)Part 1: PF-06801591 10 mg/kg (IV)Part 1: PF-06801591 300 mg (Subcutaneously [SC])Part 2: PF-06801591 300 mg (SC) for NSCLCPart 2: PF-06801591 300 mg (SC) for UCTotal
White2774125030112
Black or African American00012003
Asian0002118829
Other01100002
08

Study locations

67 sites
  • Clinical Research Unit
    Los Angeles, California 90024, United States
  • Ronald Reagan Medical Center, Department of Radiological Sciences
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center, Drug Information Center
    Los Angeles, California 90095, United States
  • UCLA Hematology & Oncology Clinic
    Los Angeles, California 90095, United States
  • Santa Monica UCLA Hematology & Oncology Clinic
    Santa Monica, California 90404, United States
  • Norton Cancer Institute, Multidisciplinary Clinic
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute, Norton Healthcare Pavilion
    Louisville, Kentucky 40202, United States
  • Norton Hospital
    Louisville, Kentucky 40202, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • UNC Hospitals, The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7600, United States
  • Tennessee Oncology, PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • Tennessee Oncology, PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37090, United States
  • Tennessee Oncology, PLLC
    Murfreesboro, Tennessee 37129, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37205, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37211, United States
  • Tennessee Oncology, PLLC
    Shelbyville, Tennessee 37160, United States
  • Tennessee Oncology, PLLC
    Smyrna, Tennessee 37167, United States
  • MHAT Uni Hospital OOD
    Panagyurishte, Pazardzhik 4500, Bulgaria
  • Complex Oncology Center - Plovdiv EOOD
    Plovdiv, 4000, Bulgaria
  • "MHAT for Women Health - Nadezhda" OOD
    Sofia, 1330, Bulgaria
  • SHATOD "Dr. Marko Antonov Markov - Varna" EOOD
    Varna, 9002, Bulgaria
  • National Cancer Center
    Goyang-si, Gyeonggi-do 10408, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Division of Medical Oncology, Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
  • Hospital Sultan Ismail
    Johor Bahru, Johor 81100, Malaysia
  • University Malaya Medical Centre
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Hospital Tengku Ampuan Afzan
    Kuantan, Pahang 25100, Malaysia
  • Clinical Research Centre(Crc), Hospital Umum Sarawak
    Kuching, Sarawak 93586, Malaysia
  • Szpitale Pomorskie Sp. z.o.o., Oddzial Onkologii i Radioterapii
    Gdynia, 81-519, Poland
  • Regionalny Szpital Specjalistyczny im. dr. Wl. Bieganskiego w Grudziadzu
    Grudziadz, 86-300, Poland
  • Centrum Badan Klinicznych JCI Life Science Park
    Krakow, 30-348, Poland
  • Mazowiecki Szpital Specjalistyczny im. Dr. Jozefa Psarskiego w Ostrolece, Osrodek Onkologiczny
    Ostroleka, 07-410, Poland
  • Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina
    Otwock, 05-400, Poland
  • Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie
    Warszawa, 02-781, Poland
  • Sbhi "Lrcod"
    Vsevolozhsky District, Leningrad Region 188663, Russian Federation
  • SBHI ¨Saint-Petersburg clinical scientific practical center of specialized types of
    Pesochny Village, Saint-petersburg 197758, Russian Federation
  • SBHI "ChRCCO and NM"
    Chelyabinsk, 454087, Russian Federation
  • MROI n.a. P.A. Gertsen, filiation of FSBI "NMRC of radiology" MoH Russia
    Moscow, 125284, Russian Federation
  • BHI of Omsk Region "Clinical Oncology Dispensary"
    Omsk, 644013, Russian Federation
  • Joint Stock Company Current medical technologies
    Saint-Petersburg, 190013, Russian Federation
  • Non-governmental Healthcare Institution ¨Railway Clinical Hospital of JSC ¨Russian Railways¨
    Saint-Petersburg, 195271, Russian Federation
  • SPb SBHI "City Clinical Oncology Dispensary"
    Saint-Petersburg, 197022, Russian Federation
  • SPb SBHI "City Clinical Oncology Dispensary"
    Saint-Petersburg, 198255, Russian Federation
  • Joint-Stock Company Current medical technologies
    St. Petersburg, 190121, Russian Federation
  • SBHI YaR ¨Regional clinical oncology hospital¨
    Yaroslavl, 150054, Russian Federation
  • Communal Non-profit Institution "City Clinical Hospital #4" of Dnipro City Council, Department of
    Dnipro, 49102, Ukraine
  • Communal non-Commercial Enterprise "Prykarpatski Clinical Oncological Center of Ivano-
    Ivano-Frankivsk, 79018, Ukraine
  • Grigoriev Radiological Institute of the National Academy of Medical Sciences of Ukraine,
    Kharkiv, 61024, Ukraine
  • Communal Non-profit Institution of Kharkiv Regional Council "Regional Clinical Specialized Health
    Kharkiv, 61166, Ukraine
  • "Specialized Clinic "Prognosis Optima" LLC
    Kyiv, 03126, Ukraine
  • Communal noncommercial enterprise Sumy regional Rada Sumy regional clinical oncologic dispensary,
    Sumy, 40030, Ukraine
  • Communal Non-profit Institution "Central City Clinical Hospital" of Uzhhorod City Council,
    Uzhhorod, 88000, Ukraine
  • Vinnytsia Regional Clinical Oncological Hospital
    Vinnytsia, 21029, Ukraine
  • Communal Institution ¨Zaporizhzhya Regional Clinical Oncological Dispensary¨
    Zaporizhzhya, 69040, Ukraine
09

References and documents

Publications

  • Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML. Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Target Oncol. 2021 Nov;16(6):773-787. doi: 10.1007/s11523-021-00833-2. Epub 2021 Oct 25. PubMed 34694529 ↗
  • Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836. PubMed 31145415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Nov 2020, 57 months.

Results were first posted in Dec 2021, 1 year after primary completion.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 57 months is above that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2015
First posted
Oct 9, 2015
StartActual
Feb 10, 2016
Primary completionActual
Nov 19, 2020
CompletionActual
Nov 19, 2020
Results first posted
Dec 13, 2021
Last update
Dec 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02573259
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Feb 10, 2016
Primary completion
Nov 19, 2020
Completion
Nov 19, 2020
Results posted
Dec 13, 2021
Last update
Dec 13, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sasanlimab

Start the discussion